Summary
LTF-TZ (research code LY3298176) is a synthetic research peptide developed as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Its dual-receptor mechanism makes it a frequently cited reference compound in comparative incretin-pharmacology literature.
Overview
LTF-TZ is a synthetic, lipidated 39-amino-acid peptide engineered to engage two distinct incretin-family receptors simultaneously. The dual-receptor design distinguishes it from single-receptor GLP-1 agonists such as LTF-SM and from the triple-receptor profile of LTF-RT.
Research Background
LTF-TZ was described by Coskun et al. (2018) in a foundational discovery paper that characterized its dual-receptor pharmacology. The design strategy was based on the observation that combining GIP- and GLP-1-receptor agonism produces metabolic effects beyond either receptor alone in preclinical models.
Mechanisms Studied
Receptor-binding studies have characterized LTF-TZ as an imbalanced agonist with higher relative activity at the GIP receptor and slightly lower activity at the GLP-1 receptor compared with native GLP-1. cAMP-accumulation and beta-arrestin recruitment assays have explored downstream signaling differences and their contribution to the compound’s in-vitro and animal-model profile.
Published Research Summary
Coskun et al. (2018, Molecular Metabolism) describe the original receptor pharmacology and preclinical characterization. Willard et al. (2020) extend the mechanistic analysis to biased agonism and beta-arrestin recruitment. Reviews by Bastin and Andreelli (2019) and others position LTF-TZ within the broader incretin-pharmacology framework.
Quality & Verification
For research compounds, lot-level documentation is the starting point for any analytical work. Researchers commonly examine batch-specific Certificates of Analysis, reversed-phase HPLC purity readouts, mass-spectrometry confirmation of molecular weight, and lot identification to evaluate compound identity, purity, and consistency before downstream experiments.
References & Published Research
- Coskun T et al. — LY3298176, a novel long-acting GIP/GLP-1 receptor co-agonist (preclinical characterization)
- Willard FS et al. — LTF-TZ is an imbalanced and biased dual GIP/GLP-1 receptor agonist
- Bastin M, Andreelli F — Dual GIP–GLP1-Receptor Agonists in the Treatment of Type 2 Diabetes: A Short Review on Emerging Data and Therapeutic Potential